Lexaria Bioscience

Lexaria Bioscience Corp., established in 2004 and headquartered in Kelowna, Canada, specializes in developing and licensing its proprietary drug delivery platform, DehydraTECH™. This technology enhances the absorption of lipophilic bioactive compounds through oral ingestion, promoting healthier administration methods, lower dosing, and higher effectiveness compared to traditional delivery methods like smoking or standard formulations. With a robust patent portfolio, DehydraTECH has been proven effective in multiple studies, demonstrating up to 27x increased bio-absorption with cannabinoids and significantly reducing the time of onset. The company generates revenue through intellectual property licensing and B2B production services, serving various industries including nicotine, pharmaceuticals, nutraceuticals, and vitamins.